Table 3.

Response status in patients with emergent mutations

	Nilotinib 300 mg twice daily (n = 282), n	Nilotinib 400 mg twice daily (n = 281), n	Imatinib 400 mg once daily (n = 283), n
Patients with mutations	11	11	21
Response status
Treatment failure*	4	6	16
Suboptimal response*	6	2	5
Confirmed loss of MMR*†	0	2	0
Other*‡	1	1	0

^*Patients were counted only once under the worst-case response category.

^†Loss of MMR was not considered a criterion for suboptimal response.

^‡The patient in the nilotinib 300 mg twice daily arm progressed after discontinuation of treatment, and the patient in the nilotinib 400 mg twice daily arm had an unconfirmed loss of MMR but regained MMR after that.